Osborne Clarke advises Scranton Enterprises on acquisition financing for its purchase of Grifols companies Biotest and Haema as part of $537m sale

Written on 30 January 2019

Osborne Clarke has advised Scranton Enterprises on the acquisition financing in relation to its $537m purchase of two companies from Grifols. The global healthcare company has sold the companies Biotest US Corporation and Haema AG to the Dutch investment group, a shareholder of the Catalan company Grifols.

The two companies were acquired by Grifols earlier in 2018 for an amount of USD 286 and EUR 220 million, respectively.

Scranton Enterprises is a private equity and venture capital firm specializing in growth capital and small and mid-caps companies. The investment company has a roughly 8.7% stake in Grifols and is owned by various directors of the Catalan company.

Grifols is currently the worldwide leader in plasma donation centres, with 190 centres in the United States. As an acknowledged market leader in the transfusion medicine, Grifols offers a wide range of diagnostic products that support the security of donations and transfusions.

An international Osborne Clarke team advised Scranton Enterprises on the transaction consisting of Peter van der Horst (Banking & Finance / Netherlands), Antje Günther and Jochen Langer (both Banking and Finance / Germany) and Eduard Arruga (Banking and Finance/ Spain), Oscar Calsamiglia and Laura de la Cruz (both Corporate / Spain). Scranton was also advised by Proskauer Rose LLP with Maximilian P. Kirchner, Jacob Durkin and Ron D. Franklin (all Banking and Finance).


Connect with one of our experts

Peter van der Horst

Senior Associate, Advocaat, The Netherlands

T +31 20 70 28656

Email Peter

Full Biog